Hyponatremia Associated with Cyclin-Dependent Kinase 4/6 Inhibitors CDK4/6i in Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Case Series and Pharmacovigilance Review (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO1235; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Introduction CDK4/6i (palbociclib, ribociclib, abemaciclib) is an FDA-approved therapy for hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer and some high-risk early-stage. CDK4/6i-associated SIADH should be considered in breast cancer patients presenting with HypoNa. Early recognition and management may allow continuation of CDK4/6i therapy while maintaining SrNa stability; larger studies are needed to define incidence and mechanisms better."
Adverse events • Clinical • Review • Breast Cancer • Heart Failure • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • HER-2
|
|
Jaymin Bakul Patel; David M. Warner; Vipulbhai Sakhiya; Kenar D. Jhaveri; Prakash Shashikant Gudsoorkar
|